10.57 -0.15 (-1.4%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 13.82 | 1-year : | 16.15 |
Resists | First : | 11.84 | Second : | 13.82 |
Pivot price | 10.33 ![]() |
|||
Supports | First : | 8.22 | Second : | 5.98 |
MAs | MA(5) : | 10.89 ![]() |
MA(20) : | 9.43 ![]() |
MA(100) : | 8.3 ![]() |
MA(250) : | 8.91 ![]() |
|
MACD | MACD : | 0.9 ![]() |
Signal : | 0.8 ![]() |
%K %D | K(14,3) : | 74.5 ![]() |
D(3) : | 80.9 ![]() |
RSI | RSI(14): 62.3 ![]() |
|||
52-week | High : | 16.62 | Low : | 5.98 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ETNB ] has closed below upper band by 43.9%. Bollinger Bands are 53.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 14 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 11.01 - 11.1 | 11.1 - 11.16 |
Low: | 10.24 - 10.34 | 10.34 - 10.4 |
Close: | 10.44 - 10.59 | 10.59 - 10.69 |
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
Thu, 13 Feb 2025
89bio, Inc. (NASDAQ:ETNB) Shares Sold by abrdn plc - MarketBeat
Sat, 08 Feb 2025
ETNB - 89bio, Inc. Latest Stock News & Market Updates - StockTitan
Thu, 06 Feb 2025
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Simply Wall St
Thu, 06 Feb 2025
Inside 89bio's Latest Executive Compensation Move: 163K Share Options Granted - StockTitan
Thu, 06 Feb 2025
Institutional investors have a lot riding on 89bio, Inc. (NASDAQ:ETNB) with 58% ownership - Yahoo Finance
Tue, 04 Feb 2025
Wolfe Research Initiates Coverage of 89bio (ETNB) with Outperform Recommendation - Nasdaq
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 139 (M) |
Shares Float | 68 (M) |
Held by Insiders | 0.6 (%) |
Held by Institutions | 89.6 (%) |
Shares Short | 8,350 (K) |
Shares Short P.Month | 6,940 (K) |
EPS | -2.97 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 3.55 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -41.4 % |
Return on Equity (ttm) | -73.4 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -2.19 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -281 (M) |
Levered Free Cash Flow | -181 (M) |
PE Ratio | -3.58 |
PEG Ratio | 0 |
Price to Book value | 2.96 |
Price to Sales | 0 |
Price to Cash Flow | -5.25 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |